Ignite Creation Date:
2024-05-05 @ 11:22 AM
Last Modification Date:
2024-10-26 @ 9:04 AM
Study NCT ID:
NCT00004169
Status:
COMPLETED
Last Update Posted:
2012-07-02
First Post:
1999-12-10
Brief Title:
Chemotherapy Radiation Therapy and Peripheral Stem Cell Transplantation in Treating Patients With Hodgkins Disease
Sponsor:
Northwestern University
Organization:
Northwestern University
Study Overview
Official Title:
High-Dose Chemoradiotherapy With Stem Cell Support in Patients With Relapsed or Refractory Hodgkins Disease
Status:
COMPLETED
Status Verified Date:
2012-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die Radiation therapy uses high-energy x-rays to damage cancer cells Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells
PURPOSE Phase II trial to study the effectiveness of chemotherapy radiation therapy and peripheral stem cell transplantation in treating patients who have recurrent or refractory Hodgkins disease
PURPOSE Phase II trial to study the effectiveness of chemotherapy radiation therapy and peripheral stem cell transplantation in treating patients who have recurrent or refractory Hodgkins disease
Detailed Description:
OBJECTIVES I Determine the toxicity and response to high dose chemotherapy and peripheral blood stem cell support in patients with recurrent or refractory Hodgkins disease II Determine the maximum tolerated dose of etoposide when combined with carboplatin and cyclophosphamide in these patients
OUTLINE This is a dose escalation study of etoposide Patients undergo total nodal radiotherapy twice a day on days -35 to -31 -28 to -24 and then radiotherapy boost once a day on days -21 to -17 Patients then receive etoposide IV continuously and carboplatin IV continuously on days -6 to -4 and cyclophosphamide IV over 2 hours on days -3 and -2 Autologous peripheral blood stem cells are infused on day 0 Patients who have received prior extensive radiation at least 2000 cGy to any site only receive chemotherapy and peripheral blood stem cell infusion Cohorts of 4-8 patients receive escalating doses of etoposide until the maximum tolerated dose MTD is determined The MTD is defined as the dose at which 1 of 4 or 2 of 8 patients experience dose limiting toxicity Patients are followed every 1-3 months for 2 years then every 3 months until death
PROJECTED ACCRUAL At least 4 patients will be accrued for this study
OUTLINE This is a dose escalation study of etoposide Patients undergo total nodal radiotherapy twice a day on days -35 to -31 -28 to -24 and then radiotherapy boost once a day on days -21 to -17 Patients then receive etoposide IV continuously and carboplatin IV continuously on days -6 to -4 and cyclophosphamide IV over 2 hours on days -3 and -2 Autologous peripheral blood stem cells are infused on day 0 Patients who have received prior extensive radiation at least 2000 cGy to any site only receive chemotherapy and peripheral blood stem cell infusion Cohorts of 4-8 patients receive escalating doses of etoposide until the maximum tolerated dose MTD is determined The MTD is defined as the dose at which 1 of 4 or 2 of 8 patients experience dose limiting toxicity Patients are followed every 1-3 months for 2 years then every 3 months until death
PROJECTED ACCRUAL At least 4 patients will be accrued for this study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NU-93H2 | None | None | None |
| NCI-G99-1636 | None | None | None |